Are Patients with Hyperlipidemia Undertreated? Study of Patients Admitted to Hospital with Coronary Events

Overview

Journal Can Fam Physician

Specialties General Medicine
Public Health

Date 2007 Sep 18

PMID 17872880

Authors

Alan H Lipson

Wendy M Fallis

Xiqui Wang

Yanqing Yi

Affiliations

Soon will be listed here.

Abstract

Objective: To identify patients admitted to hospital with coronary events and to estimate their pre-admission coronary risk, including their lipid levels. Despite the available data and numerous guidelines, evidence indicates that many patients with hyperlipidemia are undertreated and are not achieving target lipid levels.

Design: Retrospective chart review.

Setting: Acute care community hospital in Winnipeg, Man.

Participants: A total of 153 patients who were diagnosed with acute myocardial infarction, unstable angina, or acute coronary syndrome upon admission.

Method: Each patient's 10-year risk of developing coronary artery disease was calculated, and his or her risk status was established. Each patient's low-density lipoprotein cholesterol (LDL-C) levels were recorded and categorized based on current Canadian guidelines.

Results: Mean age of patients was 67.6 years; 60.8% were male. Patients in the low-risk category had a mean LDL-C level of 2.98 mmol/L (95% confidence interval [CI] 2.66 to 3.29), and patients in the moderate-risk category had a mean LDL-C level of 3.01 mmol/L (95% CI 2.74 to 3.28), both significantly lower (P < .05) than the LDL-C target levels for patients in those risk categories according to Canadian guidelines. The mean LDL-C level for patients in the very high-risk category, however, was 2.53 mmol/L (95% CI 2.35 to 2.71), above the recommended goal. Almost half the patients (48.3%) in the very high-risk category had LDL-C levels that exceeded the goal. Slightly more than 1 in 3 patients in the very high-risk category was reported to be taking lipid-lowering agents.

Conclusion: Patients in the community who are at very high risk of having cardiovascular events are undertreated with respect to attaining LDL-C target levels. These findings point to an opportunity to prevent patient morbidity and reduce the number of hospitalizations for cardiovascular events.

References

Pitt B, Waters D, Brown W, van Boven A, Schwartz L, Title L . Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med. 1999; 341(2):70-6. DOI: 10.1056/NEJM199907083410202. View

. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339(19):1349-57. DOI: 10.1056/NEJM199811053391902. View

Majumdar S, Gurwitz J, Soumerai S . Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med. 2000; 14(12):711-7. PMC: 1496865. DOI: 10.1046/j.1525-1497.1999.02229.x. View

PEARSON T, Laurora I, Chu H, Kafonek S . The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000; 160(4):459-67. DOI: 10.1001/archinte.160.4.459. View

Fodor J, Frohlich J, Genest Jr J, McPherson P . Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. CMAJ. 2000; 162(10):1441-7. PMC: 1232457. View

Teo K, Burton J, Buller C, Plante S, Catellier D, Tymchak W . Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation. 2000; 102(15):1748-54. DOI: 10.1161/01.cir.102.15.1748. View

Qureshi A, Suri M, Guterman L, Hopkins L . Ineffective secondary prevention in survivors of cardiovascular events in the US population: report from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2001; 161(13):1621-8. DOI: 10.1001/archinte.161.13.1621. View

Lambert A, Hunt M, Day A, Bayly G, Dayan C . Reproducibility of individualized coronary heart disease risk calculations in patients with diabetes mellitus. Diabet Med. 2002; 19(6):514-7. DOI: 10.1046/j.1464-5491.2002.00687.x. View

Sever P, Dahlof B, Poulter N, Wedel H, Beevers G, Caulfield M . Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre.... Lancet. 2003; 361(9364):1149-58. DOI: 10.1016/S0140-6736(03)12948-0. View

10.

Genest J, Frohlich J, Fodor G, McPherson R . Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ. 2003; 169(9):921-4. PMC: 219626. View

11.

Alzahrani T, Marrat S, Haider A . Management of dyslipidemia in primary care. Can J Cardiol. 2004; 19(13):1499-502. View

12.

. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344(8934):1383-9. View

13.

Shepherd J, Cobbe S, Ford I, Isles C, LORIMER A, Macfarlane P . Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333(20):1301-7. DOI: 10.1056/NEJM199511163332001. View

14.

Schectman G, Hiatt J . Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med. 1996; 100(2):197-204. DOI: 10.1016/s0002-9343(97)89459-4. View

15.

Sacks F, Pfeffer M, Moye L, Rouleau J, Rutherford J, Cole T . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335(14):1001-9. DOI: 10.1056/NEJM199610033351401. View

16.

Downs J, Clearfield M, Weis S, Whitney E, Shapiro D, Beere P . Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998; 279(20):1615-22. DOI: 10.1001/jama.279.20.1615. View

17.

Haffner S, Lehto S, Ronnemaa T, Pyorala K, Laakso M . Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339(4):229-34. DOI: 10.1056/NEJM199807233390404. View

18.

McPherson R, Frohlich J, Fodor G, Genest J, Canadian Cardiovascular Society . Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol. 2006; 22(11):913-27. PMC: 2570238. DOI: 10.1016/s0828-282x(06)70310-5. View